Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Master Protocol for Immune Modulators for Treating COVID-19

NCT04593940 is registered in ClinicalTrials.gov with Daniel Benjamin as lead sponsor.

NCT NCT04593940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04593940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Lead sponsor
Daniel Benjamin
Phase
Phase 3
Overall status
Completed
Start date
October 15, 2020
Completion date
March 5, 2022
Enrollment
1,971 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

covid19